Acta Neurophysiologica

Academic Strive
Researcher's perception is our reality

Opinion *Volume 4 Issue 6*

Role of MR Neuroimaging in the Future of Neurodegenerative Diseases and Neuromuscular Disorders

Ghaderi S*

Department of Neuroscience and Addiction Studies, University of Medical Sciences, Iran

***Corresponding author:** Sadegh Ghaderi, Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran, Tel: +989128535415; Email: S_ghaderi@razi.tums.ac.ir

Received Date: August 17, 2023; **Published Date:** September 08, 2023

Abstract

Neurodegenerative diseases and neuromuscular disorders impose massive individual and societal burdens. Magnetic resonance (MR) neuroimaging has emerged as an indispensable tool for evaluating many of these conditions. Conventional structural MRI provides morphological data and measures atrophy. Diffusion MRI techniques, including diffusion tensor imaging, reveal microstructural alterations, especially in white matter. Functional MRI maps abnormalities in neural connectivity and networks. MR spectroscopy detects biochemical changes in the brain. Novel quantitative mapping methods enhance subcortical iron quantification. Perfusion MRI assesses alterations in cerebral blood flow. The future of MR neuroimaging lies in multimodal integration and advanced computational analysis. Combining structural, functional, and metabolic MRI data allows multidimensional characterization of pathology. Hybrid imaging with other neuroimaging techniques and modalities further enriches the information. Machine learning and deep learning hold immense potential for extracting subtle disease signatures from big neuroimaging data. MR neuroimaging already plays a pivotal role in elucidating disease mechanisms and improving diagnosis and monitoring. Ongoing advances promise to provide even more sensitive biomarkers to detect preclinical disease stages, track progression, predict prognosis, and guide interventions. MR neuroimaging seems poised to transform the management of major neurodegenerative and neuromuscular diseases.

Keywords: Magnetic Resonance Imaging; Neuroimaging; Neurodegenerative Disease; Neuromuscular Disorder; Advanced Neuroimaging

Abbreviations: MR: Magnetic Resonance; AD: Alzheimer's Disease; PD: Parkinson's Disease; HD: Huntington's Disease; ALS: Amyotrophic Lateral Sclerosis; SMA: Spinal Muscular Atrophy; QSM; Quantitative Susceptibility Mapping; SWI: Susceptibility-Weighted Imaging; PET: Positron Emission Tomography; DTI: Diffusion Tensor Imaging; BOLD: Blood Oxygen Level-Dependent; fcMRI: Functional Connectivity MRI; Rs-fMRI: Resting-State fMRI.

Introduction

Neurodegenerative diseases and neuromuscular disorders encompass a broad spectrum of debilitating conditions that exact a heavy toll on patients, families, and society [1].

Neurodegenerative diseases like Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) involve progressive dysfunction and the death of neurons, leading to declines in movement, cognition, behavior, and more [2]. In particular, many neurodegenerative diseases significantly impair cognition, memory, and executive function. Neuromuscular disorders, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), muscular dystrophies, and myopathies, impair muscle strength and motor function through defects in motor neurons, muscle fibers, and supporting cells [3-5]. While varied in origin and manifestation, these diseases share common themes of progressive neurological deficits, disability, reduced life expectancy, and cognitive alterations [4].

As the global burden of neurodegenerative and neuromuscular diseases rises, especially in aging populations, an urgent need exists for advanced diagnostic, prognostic, and monitoring tools. Magnetic resonance (MR) neuroimaging has rapidly evolved in recent decades into an indispensable tool for evaluating many of these conditions [6,7]. Conventional structural MRI provides exquisite anatomical images, enabling the diagnosis and tracking of neurodegeneration [8,9]. Diffusion tensor imaging gives unique insights into white matter integrity [10,11]. Functional MRI reveals abnormalities in neural networks and connectivity [12,13]. MR spectroscopy detects biochemical alterations in the brain [14]. Perfusion MRI assesses alterations in cerebral blood flow that may contribute to neurodegeneration [15]. Novel techniques like quantitative susceptibility mapping (QSM) and susceptibility-weighted imaging (SWI) improve the visualization of subcortical structures affected by pathology and enhanced visualization and quantification of iron accumulation [16].

The multifaceted data generated by multimodal MRI lends itself well to advanced computational analysis using machine learning and deep learning techniques [17-19]. By identifying complex and subtle imaging patterns, machine learning methods can uncover disease biomarkers and signatures that may not be discernible by traditional methods [20]. Deep learning approaches can integrate multimodal neuroimaging data to provide enhanced diagnosis and prognostic models [21]. Ongoing research is evaluating the utility of machine learning and deep learning to leverage MRI's high-dimensional data for improved early detection, tracking progression, and predicting treatment outcomes in neurodegenerative and neuromuscular diseases. Machine learning and deep learning represent exciting frontiers for realizing the full potential of advanced MRI techniques [22,23].

Together, the array of existing and emerging MR Neuroimaging modalities allows comprehensive in vivo characterization of different facets of neuropathology. Multimodal neuroimaging data can serve as sensitive biomarkers for early diagnosis, disease staging, and response to therapy. As MR methods progress in tandem with computational analytics, they promise to shed new light on the poorly understood pathogenesis of neurodegenerative and neuromuscular diseases. MR Neuroimaging is poised to transform clinical management and accelerate therapeutic advances for these debilitating conditions. This article will provide an overview of current and cutting-edge MR techniques and their present and future applications in major neurodegenerative and neuromuscular disorders.

MR Neuroimaging

MR Neuroimaging comprises a powerful array of techniques that enable comprehensive evaluation of the structural, functional, and biochemical alterations associated with neurodegeneration and neuromuscular disorders [24-26]. The future of MR neuroimaging lies in multimodal integration and advanced computational analysis [27]. Multimodal MRI combines complementary structural, functional, and metabolic information to provide multidimensional biomarkers [28]. Hybrid imaging with positron emission tomography (PET) and other modalities further enriches data. Machine learning and deep learning hold immense potential for identifying subtle yet meaningful patterns in big neuroimaging data [29].

This Table 1 summarizes key MRI-based neuroimaging modalities, including their brief definitions, methodology, clinical utility, future directions, and possibilities for multimodal combinations. All listed techniques have shown promise for providing biomarkers, elucidating disease mechanisms, and improving diagnosis and monitoring of major neurodegenerative and neuromuscular diseases like AD, PD, HD, ALS, muscular dystrophies, and others. The multifaceted data generated from structural, functional, diffusion, susceptibility, spectroscopy, and perfusion MRI will lead to greater insights and enhanced management of these debilitating neurological conditions. Furthermore, high-level overview and the specifics of each technique and their applications can vary based on the specific disease or condition being studied. Additionally, the future potential of these techniques is dependent on ongoing research and technological advancements.

Technique	Definition	Types of Methods	Clinical Importance	Future Role
Structural MRI (Morphology and Volumetry)	Provides anatomical detail and quantifies volume loss. Measures the size, shape, and volume of brain structures.	T1-, T2-weighting; PD-w; fluid-attenuated inversion recovery (FLAIR); voxel-based morphometry (VBM); region-based morphometry (RBM); surface-based morphometry (SBM); etc.	Cerebral/spinal atrophy biomarker for neurodegeneration. Cortical thickness alterations.	Earlier pathology detection, progression tracking, and cortical abnormalities.
Diffusion-based imaging: Diffusion-weighted Imaging Diffusion Tensor Imaging (DTI) and Tractography Diffusion Kertosis Imaging (DKI)	DTI maps the diffusion process of molecules, mainly water, in biological tissues, in vivo and noninvasively. Microstructural assessment based on water diffusion.	Apparent diffusion coefficient (ADC); fractional anisotropy (FA); mean diffusivity (MD); radial diffusivity (RD); axial diffusivity (AD); The volume transfer constant (Ktrans)	Detects changes in white matter integrity, such as microstructural damage and tract disruption.	Monitor neurodegenerative diseases and white matter integrity and connectivity. Elucidate connectivity disruption.
Functional MRI (fMRI)	Detects blood oxygenation changes with neural activity and connectivity	Blood oxygen level-dependent (BOLD) imaging, functional connectivity MRI (fcMRI), and resting-state fMRI (rs-fMRI).	Detects changes in neural activity and connectivity in the brain, such as functional deficits and altered connectivity patterns	Clarify network-level dysfunction
MR Spectroscopy	proton MR spectroscopy (1H-MRS), phosphorus MR spectroscopy (31P-MRS), and carbon MR spectroscopy (13C-MRS).	Detects changes in the concentration of metabolites in the brain, such as N-acetylaspartate (NAA), choline, creatine, and myo-inositol	Biochemical alterations	Understand chemical changes
Perfusion MRI (PWI)	Measures the blood flow and volume in the brain.	Dynamic susceptibility contrast (DCE); dynamic susceptibility contrast (DSC); arterial spin labeling (ASL) imaging; bolus tracking	Detects changes in blood flow and volume in the brain, such as hypoperfusion and cerebral blood volume (CBV) changes.	Clarify vascular contributions
Susceptibility Weighted Imaging (SWI)	Sensitive to compounds affecting magnetic susceptibility	Magnitude and phase images	Iron deposition and microbleeds	Better visualization of subcortical changes.
Quantitative Susceptibility Mapping (QSM)	Quantifies magnetic susceptibility distribution	Dipole inversion methods	Iron quantification in neurodegeneration	Objective measurement of iron accumulation.
Multimodal MRI	Integration of multiple MRI techniques	Combinations of structural, DTI, fMRI, MRS, etc.	Provides multidimensional biomarker data	Holistic view of pathology and pattern analysis.

Multimodal Hybrid Neuroimaging	Combines two or more MRI techniques to provide with other neuroimaging techniques for more comprehensive information about the brain.	Multimodal MRI, multi-parameter MRI, and multi-modality imaging.	Provides more comprehensive information about the brain than any single MRI technique and/or other neuroimaging techniques.	Highly effective monitoring.
Machine Learning and Deep Learning; Integration with multimodal MRI data	Advanced computational analysis methods	Supervised and unsupervised algorithms e.g., Guide on support vector machine (SVM) and neural networks	Identify imaging biomarkers and patterns	Enhanced diagnosis, prognosis, progression tracking.

Table 1: Overview of MR neuroimaging techniques and their application in neurodegenerative diseases and neuromuscular disorders

Future Scenarios and Directions

The field of MR neuroimaging is evolving rapidly, offering promising avenues for the detection, understanding, and monitoring of neurodegenerative diseases and neuromuscular disorders. With the development of new MR techniques and computational methods, MRI has the potential to provide more comprehensive information about the brain and its diseases. This information can be used to improve the diagnosis, prognosis, and treatment of these disorders.

- Structural MRI: The future of structural MRI lies in the early detection of pathology, tracking progression, and identifying cortical abnormalities. Techniques such as voxel-based, region-based, and surface-based morphometry will play crucial roles in refining our understanding of cerebral and spinal atrophy, and cortical thickness alterations in neurodegenerative diseases [30].
- Diffusion-based imaging: These imaging techniques, including diffusion-weighted Imaging and diffusion tensor imaging (DTI), will continue to be instrumental in elucidating connectivity disruptions and changes in white matter integrity. Further refinement in these techniques might allow for even earlier detection and more nuanced understanding of microstructural damage and tract disruption in neurodegenerative disorders [31,32].
- Functional MRI: The role of fMRI will expand towards clarifying network-level dysfunctions. The increasing use of techniques like blood oxygen level-dependent (BOLD) imaging, functional connectivity MRI (fcMRI), and resting-state fMRI (rs-fMRI) will help provide deeper insights into functional deficits and altered connectivity patterns in the brain [33,34].
- MR Spectroscopy: Future direction of MR spectroscopy is likely to focus on understanding the biochemical alterations that occur in neurodegenerative diseases, through the detection of changes in the concentration of metabolites in the brain [35,36].
- Perfusion MRI (PWI): PWI is anticipated to play a larger role in clarifying vascular contributions to neurodegenerative diseases by detecting changes in blood flow and volume in the brain [37].
- Susceptibility Weighted Imaging (SWI) and Quantitative Susceptibility Mapping (QSM): These techniques will improve the visualization of subcortical changes and provide more objective measurements of iron accumulation in neurodegeneration [16,38].
- Multimodal MRI and Multimodal Hybrid Neuroimaging: The integration of multiple MRI techniques will provide a holistic view of pathology and enable pattern analysis. The combination of MRI techniques with other neuroimaging techniques will provide more comprehensive information about the brain, leading to more effective monitoring of neurodegenerative diseases [27,39,40].
- Integration of multimodal MRI data and learning algorithms: The future of MR neuroimaging will be greatly influenced by advancements in machine learning and deep learning. These computational methods will enhance the diagnosis, prognosis, and progression tracking of neurodegenerative diseases by identifying imaging biomarkers and patterns when integrated with multimodal MRI data [41,42].

Conclusion

In conclusion, the future of MR Neuroimaging is promising, with advancements in techniques, algorithms, and hardware expected to provide more comprehensive and accurate information about brain structure and function. These advancements will enable clinicians and researchers to better diagnose, treat, and monitor neurodegenerative diseases and neuromuscular disorders, leading to improved patient outcomes and quality of life.

References

1. Deneubourg C, Ramm M, Smith LJ, Baron O, Singh K, et al. (2022) The spectrum of neurodevelopmental, neuromuscular and neurodegenerative disorders due to defective autophagy. Autophagy 18(3): 496-517.

2. Ghaderi S, Karami A, Ghalyanchi LA, Abdi N, Jalali S, et al. (2023) MRI Findings in Movement Disorders and Associated Sleep d Disturbances. Am J Nucl Med Mol Imaging 13(3): 77-94.

3. Dahlqvist JR, Widholm P, Leinhard OD, Vissing J (2020) MRI in Neuromuscular Diseases: An Emerging Diagnostic Tool and Biomarker for Prognosis and Efficacy. Ann Neurol 88(4): 669-681.

4. Ghaderi S, Fatehi F, Kalra S, Batouli SAH (2023) MRI biomarkers for memory-related impairment in amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler Front Degener, pp: 1-17.

5. Backer HC, Bock J, Turner P, Johnson MA, Cunningham J, et al. (2022) Juvenile muscular atrophy of the distal upper extremity (Hirayama syndrome): a systematic review. Eur Spine J 31(12): 296-307.

6. Mazon M, Vazquez CJF, Ten EA, Marti BL (2018) Imaging Biomarkers for the Diagnosis and Prognosis of Neurodegenerative Diseases. The Example of Amyotrophic Lateral Sclerosis. Front Neurosci 12: 784.

7. Wareham LK, Liddelow SA, Temple S, Benowitz LI, Polo AD, et al. (2022) Solving neurodegeneration: common mechanisms and strategies for new treatments. Mol Neurodegener 17: 23.

8. Ghaderi S, Olfati M, Ghaderi M, Hadizadeh H, Yazdanpanah G, et al. (2023) Neurological manifestation in COVID-19 disease with neuroimaging studies. Am J Neurodegener Dis 12(2): 42-84.

9. Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6(2): 67-77.

10. Chanraud S, Zahr N, Sullivan EV, Pfefferbaum A (2010) MR Diffusion Tensor Imaging: A Window into White Matter Integrity of the Working Brain. Neuropsychol Rev 20(2): 209-225.

11. Raghavan S, Reid RI, Przybelski SA, Lesnick TG, Graff RJ, et al. (2021) Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Commun 3(2): fcab106.

12. Tomson SN, Schreiner MJ, Narayan M, Rosser T, Enrique N, et al. (2015) Resting state functional MRI reveals abnormal network connectivity in neurofibromatosis 1. Hum Brain Mapp 36(11): 4566-4581.

13. Clayden JD (2013) Imaging connectivity: MRI and the structural networks of the brain. Funct Neurol 28(3): 197-203.

14. Huang BY, Kwock L, Castillo M, Smith JK (2010) Association of Choline Levels and Tumor Perfusion in Brain Metastases Assessed with Proton MR Spectroscopy and Dynamic Susceptibility Contrast-enhanced Perfusion Weighted MRI. Technol Cancer Res Treat 9(4): 327-337.

15. Essig M, Nguyen TB, Shiroishi MS, Saake M, Provenzale JM, et al. (2013) Perfusion MRI: The Five Most Frequently Asked Clinical Questions. AJR Am J Roentgenol 201(3): W495-510.

16. Liu C, Li W, Tong KA, Yeom KW, Kuzminski S (2015) Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. J Magn Reson Imaging JMRI 42(1): 23-41.

17. Jeong JW, Lee MH, John F, Robinette NL, Amit YAJ, et al. (2019) Feasibility of Multimodal MRI-Based Deep Learning Prediction of High Amino Acid Uptake Regions and Survival in Patients With Glioblastoma. Front Neurol 10: 1305.

18. He L, Li H, Chen M, Wang J, Altaye M, et al. (2021) Deep Multimodal Learning From MRI and Clinical Data for Early Prediction of Neurodevelopmental Deficits in Very Preterm Infants. Front Neurosci 15: 753033.

19. Ghaderi S (2023) Fractal Dimension Image Processing for Feature Extraction and Morphological Analysis: Gd3+/13X/DOX/FA MRI Nanocomposite. J Nanomater. pp: 11.

20. Davatzikos C, Sotiras A, Fan Y, Habes M, Erus G, et al. (2019) Precision diagnostics based on machine learning-derived imaging signatures. Magn Reson Imaging 64: 49-61.

21. Jo T, Nho K, Saykin AJ (2019) Deep Learning in Alzheimer's Disease: Diagnostic Classification and Prognostic Prediction Using Neuroimaging Data. Front Aging Neurosci 11: 220.

22. Khaliq F, Oberhauser J, Wakhloo D, Mahajani S (2023) Decoding degeneration: the implementation of machine learning for clinical detection of neurodegenerative disorders. Neural Regen Res 18(6): 1235-1242.

23. Duong MT, Rauschecker AM, Mohan S (2020) Diverse Applications of Artificial Intelligence in Neuroradiology.

Neuroimaging Clin N Am 30(4): 505-516.

24. Angelini C, Pinzan E (2019) Advances in imaging of brain abnormalities in neuromuscular disease. Ther Adv Neurol Disord 12:1756286419845567.

25. Kassubek J, Ludolph AC, Muller HP (2012) Neuroimaging of motor neuron diseases. Ther Adv Neurol Disord 5(2): 119-127.

26. Ghaderi S, Mohammadi S, Heidari M, Sharif JSS, Mohammadi M (2023) Post-COVID-19 Vaccination CNS Magnetic Resonance Imaging Findings: A Systematic Review. Can J Infect Dis Med Microbiol 2023: e1570830.

27. Liu S, Cai W, Liu S, Zhang F, Fulham M, et al. (2015) Multimodal neuroimaging computing: a review of the applications in neuropsychiatric disorders. Brain Inform 2(3): 167-180.

28. Lin AL, Laird AR, Fox PT, Gao JH (2011) Multimodal MRI Neuroimaging Biomarkers for Cognitive Normal Adults, Amnestic Mild Cognitive Impairment, and Alzheimer's Disease. Neurol Res Int 2012: e907409.

29. Zaharchuk G (2019) Next Generation Research Applications for Hybrid PET/MR and PET/CT Imaging Using Deep Learning. Eur J Nucl Med Mol Imaging 46(13): 2700-2907.

30. Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, et al. (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7(7): 615-625.

31. Sun Z, Parra C, Bang JW, Fieremans E, Wollstein G, et al. (2020) Diffusion Kurtosis Imaging Reveals Optic Tract Damage That Correlates with Clinical Severity in Glaucoma. Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Int Conf 2020: 1746-1749.

32. Huisman TAGM (2010) Diffusion-weighted and diffusion tensor imaging of the brain, made easy. Cancer Imaging 10(1A): S163-171.

33. Glover GH (2011) Overview of Functional Magnetic Resonance Imaging. Neurosurg Clin N Am 22(2): 133-139.

34. Lv H, Wang Z, Tong E, Williams LM, Zaharchuk G, et al. (2018) Resting-State Functional MRI: Everything That Nonexperts Have Always Wanted to Know. AJNR Am J Neuroradiol 39(8): 1390-1399.

35. Oz G, Alger JR, Barker PB, Bartha R, Bizzi A, et al. (2014) Clinical Proton MR Spectroscopy in Central Nervous System Disorders. Radiology 270(3): 658-679.

36. Oz G (2013) MR Spectroscopy in Health and Disease. In: Manto M, et al. (Eds.), Handbook of the Cerebellum and Cerebellar Disorders. Dordrecht: Springer Netherlands, pp: 713-733.

37. Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, et al. (2020) Imaging biomarkers in neurodegeneration: current and future practices. Alzheimers Res Ther 12(1): 49.

38. Harada T, Kudo K, Fujima N, Yoshikawa M, Ikebe Y, et al. (2022) Quantitative Susceptibility Mapping: Basic Methods and Clinical Applications. RadioGraphics 42(4): 1161-1176.

39. Salvador R, Canales RE, Guerrero PA, Sarro S, Tordesillas GD, et al. (2019) Multimodal Integration of Brain Images for MRI-Based Diagnosis in Schizophrenia. Front Neurosci 13: 1203.

40. Banihashemi L, Lv J, Wu M, Zhan L (20232) Editorial: Current advances in multimodal human brain imaging and analysis across the lifespan: From mapping to state prediction. Front Neurosci.17: 1153035.

41. Garcia SCB, Husch A, Hertel F (2023) Machine learning models for diagnosis and prognosis of Parkinson's disease using brain imaging: general overview, main challenges, and future directions. Front Aging Neurosci 15: 1216163.

42. Zhang L, Wang M, Liu M, Zhang D (2020) A Survey on Deep Learning for Neuroimaging-Based Brain Disorder Analysis. Front Neurosci 14: 779.